Compare MLTX & GAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLTX | GAM |
|---|---|---|
| Founded | 2021 | 1927 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2020 | N/A |
| Metric | MLTX | GAM |
|---|---|---|
| Price | $19.93 | $64.64 |
| Analyst Decision | Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $27.50 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 29.4K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 5.74% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 11.67 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $5.50 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.95 | $56.24 |
| 52 Week High | $62.75 | $66.18 |
| Indicator | MLTX | GAM |
|---|---|---|
| Relative Strength Index (RSI) | 55.88 | 59.18 |
| Support Level | $15.54 | $62.27 |
| Resistance Level | $21.00 | $66.00 |
| Average True Range (ATR) | 1.06 | 0.77 |
| MACD | -0.11 | 0.19 |
| Stochastic Oscillator | 27.74 | 88.53 |
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
General American Investors Co Inc is a closed-end, diversified management investment company. The primary investment objective of the company is long-term capital appreciation through investment in companies with above-average growth potential. It focuses on equity securities with growth potential at reasonable valuations. The company invests principally in common stocks believed by management to have growth potential.